Last reviewed · How we verify
DepoCyte
DepoCyte is a sustained-release formulation of cytarabine that delivers chemotherapy directly into the cerebrospinal fluid to treat hematologic malignancies affecting the central nervous system.
DepoCyte is a sustained-release formulation of cytarabine that delivers chemotherapy directly into the cerebrospinal fluid to treat hematologic malignancies affecting the central nervous system. Used for Lymphomatous meningitis, Leukemic meningitis.
At a glance
| Generic name | DepoCyte |
|---|---|
| Sponsor | PETHEMA Foundation |
| Drug class | Liposomal chemotherapy (nucleoside antimetabolite) |
| Target | DNA synthesis (cytarabine acts as a nucleoside analog) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
DepoCyte is liposomal cytarabine designed for intrathecal administration, providing prolonged drug exposure in the cerebrospinal fluid. The liposomal formulation allows for extended release of cytarabine, reducing the frequency of intrathecal injections compared to conventional cytarabine while maintaining cytotoxic activity against leukemic cells in the CNS.
Approved indications
- Lymphomatous meningitis
- Leukemic meningitis
Common side effects
- Arachnoiditis
- Headache
- Neurotoxicity
- Myelosuppression
- Fever
Key clinical trials
- Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL (PHASE2)
- Safety and Feasibility Study of Combination of State of Art Chemoimmunotherapy, Intensive Central Nervous System Prophylaxis and Scrotal Irradiation to Treat Primary Diffuse Large B-cell Lymphoma of Testis (PHASE2)
- High-dose Sequential Chemoimmunotherapy for B-cell Lymphomas With Central Nervous System Involvement (PHASE2)
- German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (PHASE4)
- Nordic Study in Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma (PHASE2)
- CHemoImmunotherapy With Early Central Nervous System (CNS) Prophylaxis (PHASE2)
- Interest of Intrathecal Chemotherapy With Liposomal Cytarabine (DepoCyte®) in Meningeal Metastasis of Breast Cancer (PHASE3)
- Phase II Study to Evaluate the Combination of Rituximab and DepoCyte® in the C5R Chemotherapy Protocol in Patients Between the Ages of 18 and 60 Years With Primary Cerebral Non-Hodgkin Lymphoma and Systemic Diffuse Large B-cell Lymphoma With Neuromeningeal Invasion at Diagnosis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DepoCyte CI brief — competitive landscape report
- DepoCyte updates RSS · CI watch RSS
- PETHEMA Foundation portfolio CI